Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) EPS (Basic) (2016 - 2025)

BioCorRx's EPS (Basic) history spans 15 years, with the latest figure at -$0.08 for Q2 2025.

  • For Q2 2025, EPS (Basic) rose 40.24% year-over-year to -$0.08; the TTM value through Jun 2025 reached -$0.08, up 40.24%, while the annual FY2024 figure was -$0.49, 8.09% down from the prior year.
  • EPS (Basic) for Q2 2025 was -$0.08 at BioCorRx, down from -$0.06 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.06 in Q1 2025 and bottomed at -$0.26 in Q1 2021.
  • The 5-year median for EPS (Basic) is -$0.14 (2022), against an average of -$0.14.
  • The largest annual shift saw EPS (Basic) crashed 42.86% in 2021 before it soared 60.06% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.19 in 2021, then grew by 14.66% to -$0.16 in 2022, then rose by 28.31% to -$0.12 in 2023, then decreased by 0.92% to -$0.12 in 2024, then soared by 30.99% to -$0.08 in 2025.
  • Per Business Quant, the three most recent readings for BICX's EPS (Basic) are -$0.08 (Q2 2025), -$0.06 (Q1 2025), and -$0.12 (Q4 2024).